Sugi Predict

Sugi Predict / Compounds / SCHEMBL14739090

SCHEMBL14739090

SCHEMBL14739090

C[N+](C)(C)CC(CCO)OP(=O)([O-])O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ HRH1 P35367 1/20 0.35
▸ CYP2C19 P33261 2/20 0.33
▸ RECQL P46063 1/20 0.33
▸ SLC25A20 O43772 3/20 0.32
▸ TP53 P04637 2/20 0.32
▸ CYP2D6 P10635 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ THPO P40225 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ SLC6A5 Q9Y345 1/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1692410 0.86 MEN1 (0.37) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL8160112 0.85 SMPD1 (0.45) MEN1KMT2ACYP1A2CYP2C19SLC25A20
SCHEMBL14739986 0.84 GABBR2 (0.36) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL5255308 0.84 MEN1 (0.34) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL62053 0.83 SMPD1 (0.47) MEN1KMT2ACYP2C19SLC25A20TP53
SCHEMBL4638950 0.83 SMPD1 (0.47) MEN1KMT2ACYP2C19SLC25A20TP53
SCHEMBL60847 0.83 SMPD1 (0.47) MEN1KMT2ACYP2C19SLC25A20TP53
SCHEMBL418811 0.83 SMPD1 (0.47) MEN1KMT2ACYP2C19SLC25A20TP53
SCHEMBL2693658 0.83 SMPD1 (0.47) MEN1KMT2ACYP2C19SLC25A20TP53
SCHEMBL60425 0.83 SMPD1 (0.47) MEN1KMT2ACYP2C19SLC25A20TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371211-B2 Packaging solutions BAUSCH + LOMB IRELAND LIMITED (IE) 2025-07-29 — — US disclosed
US-20250154289-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2025-05-15 — — US disclosed
US-12227598-B2 Glycophospholipid polymeric network and use thereof BAUSCH & LOMB INCORPORATED (US) 2025-02-18 — — US disclosed
US-20250040673-A1 PACKAGING SOLUTIONS JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2025-02-06 — — US disclosed
US-20240270419-A1 PACKAGING SOLUTIONS JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-08-15 — — US disclosed
US-12012238-B2 Packaging solutions BAUSCH + LOMB IRELAND LIMITED (IE) 2024-06-18 — — US disclosed
EP-4346922-A2 PACKAGING SOLUTIONS Bausch + Lomb Ireland Limited (IE) 2024-04-10 — — EP disclosed
US-20230257485-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2023-08-17 — — US disclosed
US-11673974-B2 Glycophospholipid polymeric network and use thereof BAUSCH & LOMB INCORPORATED (US) 2023-06-13 — — US disclosed
US-20220411115-A1 PACKAGING SOLUTIONS JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2022-12-29 — — US disclosed
CN-114437128-A Choline phosphate modified paclitaxel medicine and preparation method and application thereof 中国科学院长春应用化学研究所 2022-05-06 — — CN disclosed
EP-3962961-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF Bausch & Lomb Incorporated (US) 2022-03-09 — — EP disclosed
CN-114096567-A Glycophospholipid polymer networks and uses thereof 鲍希与洛姆伯股份有限公司 2022-02-25 — — CN disclosed
WO-2020222914-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF BAUSCH & LOMB INCORPORATED (US) 2020-11-05 — — WO disclosed
US-20200339710-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF BAUSCH HEALTH US, LLC 2020-10-29 — — US disclosed
EP-2751123-B1 BIOCOMPATIBLE MATERIAL VERTELLUS HOLDINGS LLC (US) 2017-08-02 — — EP disclosed
US-9006305-B2 Biocompatible material VERTELLUS SPECIALTIES INC. (US) 2015-04-14 — — US disclosed
EP-2751123-A1 BIOCOMPATIBLE MATERIAL Vertellus Specialties Inc. (US) 2014-07-09 — — EP disclosed
WO-2013033554-A1 BIOCOMPATIBLE MATERIAL VERTELLUS SPECIALTIES INC. (US) 2013-03-07 — — WO disclosed
US-20130059970-A1 BIOCOMPATIBLE MATERIAL VERTELLUS HOLDINGS, LLC 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154289-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF ALG1, CSGALNACT1, FUT6 MEN1 2468/4885KMT2A 4072/4885CYP1A2 3279/4885
US-11673974-B2 Glycophospholipid polymeric network and use thereof ALG1, CSGALNACT1, FUT5 MEN1 2971/4885KMT2A 4510/4885CYP1A2 3850/4885
US-20200339710-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF ALG1, CSGALNACT1, FUT5 MEN1 2971/4885KMT2A 4510/4885CYP1A2 3850/4885
US-20130059970-A1 BIOCOMPATIBLE MATERIAL VCL, ITGAM, MACF1 MEN1 550/4885KMT2A 3893/4885CYP1A2 2759/4885
US-20230257485-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF ALG1, CSGALNACT1, FUT6 MEN1 2468/4885KMT2A 4072/4885CYP1A2 3279/4885
US-12227598-B2 Glycophospholipid polymeric network and use thereof ALG1, CSGALNACT1, FUT6 MEN1 2468/4885KMT2A 4072/4885CYP1A2 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.